{{Rsnum
|rsid=7177792
|Gene=ABHD2
|Chromosome=15
|position=89117808
|Orientation=plus
|GMAF=0.3861
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ABHD2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 34.5 | 46.0 | 19.5
| HCB | 65.0 | 30.7 | 4.4
| JPT | 69.0 | 28.3 | 2.7
| YRI | 8.2 | 38.4 | 53.4
| ASW | 10.5 | 47.4 | 42.1
| CHB | 65.0 | 30.7 | 4.4
| CHD | 67.0 | 28.4 | 4.6
| GIH | 28.7 | 53.5 | 17.8
| LWK | 18.2 | 40.0 | 41.8
| MEX | 57.9 | 31.6 | 10.5
| MKK | 18.7 | 46.5 | 34.8
| TSI | 33.3 | 57.8 | 8.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7177792
|Name_s=
|Gene_s=ABHD2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109305
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7177792
|overall_frequency_n=66
|overall_frequency_d=128
|overall_frequency=0.515625
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=58
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}